Case Report: Long-acting growth hormone initiated at 6 months of age in molecularly confirmed Silver-Russell syndrome
Frontiers in Endocrinology · 20.11.2026 · 17
DOI: 10.3389/fendo.2026.2015632 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Endocrinology, online erschienen am 20.11.2026. Verfasst von Mengyuan Liu und 2 weiteren Autor:innen. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Evidence concerning growth hormone (GH) treatment initiated during infancy in Silver-Russell syndrome (SRS) remains limited. We describe a boy born small for gestational age with persistent feeding difficulties, growth restriction, and limb asymmetry. Methylation-specific multiplex ligation-dependent probe amplification identified 11p15.5 imprinting control region 1 hypomethylation at approximately 5 months. Weekly PEGylated recombinant human GH was initiated at 6 months because of molecularly confirmed SRS and marked growth restriction with feeding difficulties despite nutritional support; GH deficiency was not established. The target dose was 0.2 mg/kg/week, with recorded doses increasing from 1.0 to 2.5 mg/week. Treatment was interrupted for approximately 1 month during pneumonia. From 6 to 55 months, length/height increased from 62.1 to 103.5 cm and weight from 5.3 to 14.3 kg. World Health Organization length/height-for-age standard deviation score (SDS) increased from −2.58 to −0.84, a change of +1.75 SDS. Nutritional support included high-calorie formula until approximately 18 months. Available glucose and glycated hemoglobin results showed no apparent deterioration, but unavailable insulin-like growth factor 1 (IGF-1) SDS and absent latest biochemistry limit safety assessment. Follow-up blood samples were obtained before the scheduled weekly dose. At 56 months, caregiver-completed Ages and Stages Questionnaires, Third Edition screening yielded domain scores of 50–60/60, with residual motor concerns. This case describes an individualized course with approximately 49 months of growth follow-up; concurrent nutritional intervention and the absence of a comparator preclude attributing growth changes solely to GH or establishing the safety of infant initiation.
Zitieren
APA
Liu, M., Xing, Y., & Wang, X. (2026). Case Report: Long-acting growth hormone initiated at 6 months of age in molecularly confirmed Silver-Russell syndrome. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2015632
Vancouver
Liu M, Xing Y, Wang X. Case Report: Long-acting growth hormone initiated at 6 months of age in molecularly confirmed Silver-Russell syndrome. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2015632
BibTeX
@article{Liu2026,
author = {Liu, Mengyuan and Xing, Yan and Wang, Xinli},
title = {Case Report: Long-acting growth hormone initiated at 6 months of age in molecularly confirmed Silver-Russell syndrome},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2015632}
}
EUVIMED